1. Home
  2. MXE vs SABS Comparison

MXE vs SABS Comparison

Compare MXE & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mexico Equity and Income Fund Inc. (The)

MXE

Mexico Equity and Income Fund Inc. (The)

HOLD

Current Price

$12.34

Market Cap

54.4M

Sector

Finance

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.67

Market Cap

181.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXE
SABS
Founded
1990
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.4M
181.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MXE
SABS
Price
$12.34
$3.67
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$10.50
AVG Volume (30 Days)
5.8K
317.2K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
2.66%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$114,698.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.40
$1.00
52 Week High
$11.51
$6.60

Technical Indicators

Market Signals
Indicator
MXE
SABS
Relative Strength Index (RSI) 63.42 46.38
Support Level $11.91 $3.77
Resistance Level $12.74 $4.00
Average True Range (ATR) 0.23 0.21
MACD 0.00 -0.05
Stochastic Oscillator 51.54 22.72

Price Performance

Historical Comparison
MXE
SABS

About MXE Mexico Equity and Income Fund Inc. (The)

Mexico Equity and Income Fund Inc. is a closed-end, non-diversified management investment company that aims for long-term capital appreciation and current income. It prominently invests in equity, convertible securities, and debt issued by Mexican companies, operating across various sectors. The fund benchmarks its performance against the Mexbol and MSCI Mexico Index. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: